To see if these treatments also effect melanoma cells, we repeated the experiment with B16-F10 cells and observed a decrease in the activating phosphorylation sites of STAT1 and MHCII (Fig. 2C, Fig. S2C). The gene discussed is STAT1; the disease is melanoma.